MRMichael Rusch

Michael Rusch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Rusch has a total of 742 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer

    by Samuel W. Brady, Michael A. Arnold, Mingjuan Wang, Ramzi Alsallaq, Li Dong, Mohammad Aslam Khan, Wentao Yang, Kayla L. Stratton, Wei Liu, Yan Chen, et al.

    Childhood cancer survivors have a heightened risk of developing subsequent neoplasms (SN) related to therapy. We analyzed whole-genome, exome, and RNA sequencing of 200 breast, meningioma, and thyroid SNs, which developed a median of 26.4 years after childhood cancer, among 160 survivors. Meningioma and thyroid SNs were enriched for driver gene rearrangements compared with de novo tumors, including NF2-disrupting alterations and kinase fusions potentially induced by radiation. Radiation correlated with increased insertion–deletion signature ID5. Nitrogen mustard treatment correlated with elevated “flat” signature SBS5 in breast and meningioma SNs; in vitro, these agents caused an unresolved flat signature associated with multiple flat signatures from the Catalogue of Somatic Mutations in Cancer. In meningioma, platinum therapy correlated with NF2 splice-site variants. Analysis of 19 multisample survivors revealed intrapatient heterogeneity in meningioma, including clonally independent tumors. These results demonstrate the long-term impact of childhood cancer treatment on the genomes of SNs developing in adulthood, which may guide SN treatment and prevention. Significance:This represents the most comprehensive genomic characterization of SNs from childhood cancer survivors to date, revealing the mutagenic impact of multiple therapies on the SN genome, including the potential impact of nitrogen mustards such as cyclophosphamide. These results may guide the optimization of future cancer treatment regimens to prevent SN development.See related commentary by Bertrums and van Boxtel, p. 1483

  • Open Access

    Supplementary Figures S1-S22 from Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer

    by Samuel W. Brady, Michael A. Arnold, Mingjuan Wang, Ramzi Alsallaq, Li Dong, Mohammad Aslam Khan, Wentao Yang, Kayla L. Stratton, Wei Liu, Yan Chen, et al.

    Supplementary Figure S1 shows SN sample exclusion, sequencing coverage, and sequencing types. Supplementary Figure S2 shows filtering approaches for exome FFPE artefacts in 33 pediatric tumors with matched FFPE vs. fresh-frozen data. Supplementary Figure S3 shows the correlation between SNV burden in SN exome vs. WGS data. Supplementary Figure S4 shows TCGA exome SNV and indel burden analysis for de novo cancer cohorts. Supplementary Figure S5 shows coverage data and absence of significant coverage effects on mutation burdens. Supplementary Figure S6 shows a comparison of SNV, indel, and SV burdens in 8 ovarian tumors with matched FFPE vs. fresh-frozen data. Supplementary Figure S7 shows de novo signature extraction data for SNV and indel signatures. Supplementary Figure S8 shows SNV signature data for thyroid SNs and dose-response analysis in meningioma SNs. Supplementary Figure S9 shows drug dose response curves in MCF10A cells. Supplementary Figure S10 shows the cisplatin signature in MCF10A cells. Supplementary Figure S11 shows additional details of experimental drug signatures and comparison signatures from other experimental studies. Supplementary Figure S12 shows the effects of simulated 4-OH-cyclophosphamide treatment on SNV signatures in patient tumors. Supplementary Figure S13 shows doublet signatures in SNs. Supplementary Figure S14 shows meningioma SN copy profiles. Supplementary Figure S15 shows details of functional NF2 splicing assays. Supplementary Figure S16 shows how probabilities were predicted for NF2 variant induction by platinum signatures. Supplementary Figure S17 shows breast SN copy profiles. Supplementary Figure S18 shows clonal evolution trees for breast, meningioma, and thyroid SNs. Supplementary Figure S19 shows details of clonal evolution in breast SNs. Supplementary Figure S20 shows details of clonal evolution in meningioma SNs. Supplementary Figure S21 shows details of clonal evolution in thyroid SNs. Supplementary Figure S22 shows selection of high-quality WGS samples for mutational signature analysis based on coverage breadth

  • Open Access

    Supplementary Tables S1-S26 from Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer

    by Samuel W. Brady, Michael A. Arnold, Mingjuan Wang, Ramzi Alsallaq, Li Dong, Mohammad Aslam Khan, Wentao Yang, Kayla L. Stratton, Wei Liu, Yan Chen, et al.

    Supplementary Table S1 shows SN sample clinical variables and metadata. Supplementary Table S2 shows a comparison of variables between good-quality vs. excluded samples. Supplementary Table S3 shows a summary of prior treatments across SN patients. Supplementary Table S4 shows a summary of original childhood cancer diagnoses for SN patients. Supplementary Table S5 shows metadata for 33 pediatric cancers with matched FFPE and fresh-frozen exome data. Supplementary Table S6 shows a list of coding-region somatic SNVs used for mutation burden analysis. Supplementary Table S7 shows multivariable analysis comparing SNV burdens between cohorts. Supplementary Table S8 shows multivariable analysis comparing age between cohorts. Supplementary Table S9 shows multivariable analysis comparing SNV burdens between thyroid cancer cohorts among samples with coverage below 100x. Supplementary Table S10 shows cancer-predisposing germline alterations among SN patients. Supplementary Table S11 shows a list of coding-region somatic indels used for mutation burden analysis. Supplementary Table S12 shows multivariable analysis comparing indel burdens between cohorts. Supplementary Table S13 shows SNV signature levels among SNs. Supplementary Table S14 shows multivariable analysis comparing SBS5 burdens in breast SNs stratified by prior treatment. Supplementary Table S15 shows multivariable analysis comparing SBS5 burdens in meningioma SNs stratified by prior treatment. Supplementary Table S16 shows multivariable analysis testing SBS5-cyclophosphamide dose-response relationship in meningioma SNs. Supplementary Table S17 shows variation in cyclophosphamide-containing regimens among meningioma SNs. Supplementary Table S18 shows indel signature levels among SNs. Supplementary Table S19 shows multivariable analysis testing ID5-radiation dose-response relationship in each SN type. Supplementary Table S20 shows multivariable analysis testing ID5-radiation dose-response relationship with all 3 SN types combined. Supplementary Table S21 shows NF2-disrupting structural variants detected in meningioma SNs. Supplementary Table S22 shows multivariable analysis comparing driver alteration frequency between meningioma cohorts. Supplementary Table S23 shows driver fusions in thyroid SNs. Supplementary Table S24 shows multivariable analysis comparing mutation group frequency between thyroid cancer cohorts. Supplementary Table S25 shows multivariable analysis comparing driver alteration frequency between thyroid cancer cohorts. Supplementary Table S26 shows multivariable analysis comparing driver alteration frequency between breast cancer cohorts

  • Open Access

    Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer

    by Samuel W. Brady, Michael A. Arnold, Mingjuan Wang, Ramzi Alsallaq, Li Dong, Mohammad Aslam Khan, Wentao Yang, Kayla L. Stratton, Wei Liu, Yan Chen, et al.

    Childhood cancer survivors have a heightened risk of developing subsequent neoplasms (SN) related to therapy. We analyzed whole-genome, exome, and RNA sequencing of 200 breast, meningioma, and thyroid SNs, which developed a median of 26.4 years after childhood cancer, among 160 survivors. Meningioma and thyroid SNs were enriched for driver gene rearrangements compared with de novo tumors, including NF2-disrupting alterations and kinase fusions potentially induced by radiation. Radiation correlated with increased insertion–deletion signature ID5. Nitrogen mustard treatment correlated with elevated “flat” signature SBS5 in breast and meningioma SNs; in vitro, these agents caused an unresolved flat signature associated with multiple flat signatures from the Catalogue of Somatic Mutations in Cancer. In meningioma, platinum therapy correlated with NF2 splice-site variants. Analysis of 19 multisample survivors revealed intrapatient heterogeneity in meningioma, including clonally independent tumors. These results demonstrate the long-term impact of childhood cancer treatment on the genomes of SNs developing in adulthood, which may guide SN treatment and prevention. Significance: This represents the most comprehensive genomic characterization of SNs from childhood cancer survivors to date, revealing the mutagenic impact of multiple therapies on the SN genome, including the potential impact of nitrogen mustards such as cyclophosphamide. These results may guide the optimization of future cancer treatment regimens to prevent SN development.


  • Characterization of Genetic Etiologic Factors for Pediatric Acute Lymphoblastic Leukemia in Large Childhood Cancer Survivorship Cohorts

    by Xiaoxi Meng, Cheng Chen, Na Qin, Heather L. Mulder, John Easton, Michael N. Edmonson, Michael Rusch, Jinghui Zhang, Jason R. Myers, Logan G. Spector, et al.

    Background: Germline genetic susceptibility to pediatric acute lymphoblastic leukemia (pALL) remains incompletely characterized across the allelic spectrum, including ultrarare, high-penetrance cancer-predisposing variants (CPV). Methods: We analyzed germline genetic data from 3,208 pALL survivors, 7,821 non-pALL survivors, and 377 noncancer controls from the St. Jude Lifetime Cohort Study and the Childhood Cancer Survivor Study. We evaluated enrichment of ultrarare CPVs in 60 curated cancer predisposition genes and conducted a genome-wide association study (GWAS) meta-analysis of common and low-frequency variants. Results: Compared with noncancer controls, pALL survivors showed significant enrichment of ultrarare CPVs in BRCA1, PALB2, and PTPN11, in addition to established susceptibility genes CDKN2A and TP53. GWAS meta-analysis replicated 93% of previously reported pALL risk variants, with 7 loci achieving genome-wide significance (P < 5 × 10−8). Two novel variants were identified: rs112425636 within secreted and transmembrane protein 1 [SECTM1; odds ratio (OR) = 1.60; 95% confidence interval (CI), 1.39–1.84; P = 2.77 × 10−11] and rs1821340 at 8q24.21 (OR = 1.33; 95% CI, 1.22–1.44; P = 1.63 × 10−11). The rs112425636 risk allele was associated with reduced SECTM1 expression in B-cell pALL tumors. The median polygenic risk score was significantly higher in pALL survivors than in non-pALL survivors and noncancer controls (P = 6.64 × 10−147). Single-nucleotide polymorphism–based heritability was 0.19 (standard error = 0.054). Conclusions: This study comprehensively characterizes the genetic etiology of pALL by integrating ultrarare and common germline variations, expanding the spectrum of inherited risk factors. Impact: These findings advance the understanding of pALL genetic architecture and inform future risk stratification.


  • Open Access

    Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers

    by D Bennett, M Wierdl, S Chakraborty, Jd Johnson, V Akingbehin, D Estevez-Prado, Y Feng, Jj Morsby, J Harper, Ma Mohammad Nezhady, et al.

    Alternative lengthening of telomeres (ALT) is a telomerase-independent pathway used by aggressive cancers to maintain their replicative immortality. Because ALT is absent from normal human cells, it is an appealing target for cancer therapy, but the lack of ability to determine ALT status at scale has hindered discovery. Here, we developed ALTitude, a machine learning method from a tabular foundation model that infers ALT from cell line whole genome sequencing data, without need for paired germline analysis. We deployed ALTitude across the DepMap, doubling the number of known ALT+ cancer models. Systematic integration of ALTitude with CRISPR-Cas9 screens yielded the selective dependency on SMARCAL1 in ALT+ cell lines, where we show it stabilizes the ALT phenotype. Acute depletion of SMARCAL1 leads to G2/M arrest, mitotic catastrophe, and cell death. These data provide a valuable resource for studying ALT-related genomic features and present SMARCAL1 as a therapeutic target for ALT+ malignancies.


  • Open Access

    Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment

    by Rebecca K. Voss, Victor B. Pastor Loyola, Maria F. Cardenas, Priya Kumar, Jamie L. Maciaszek, Maria Namwanje, Jing Ma, Jennifer L. Neary, Meiling Jin, Masayuki Umeda, et al.

    Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic implications. Cytogenetics study, along with Next Generation Sequencing (NGS) panel testing, have long been the standard for molecular diagnosis of AML. While these approaches enable diagnosis and prognosis determination in most cases, they have limitations—particularly in detecting emerging rare, recurrent genetic abnormalities. In this study, we systematically reviewed our real-time clinical experience with the diagnostic workup of pediatric AML using an integrated whole genome and whole transcriptome sequencing (iWGS-WTS) approach and compared the test results obtained from various methodologies, including whole genome sequencing (WGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS), iWGS-WTS, cytogenetics, and targeted panel NGS. Our findings demonstrate that the iWGS-WTS approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Additionally, the iWGS-WTS approach streamlines sample acquisition and reduces testing redundancy, positioning it as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.


  • Open Access

    scMINER: a mutual information-based framework for clustering and hidden driver inference from single-cell transcriptomics data

    by Qingfei Pan, Liang Ding, Siarhei Hladyshau, Xiangyu Yao, Jiayu Zhou, Lei Yan, Yogesh Dhungana, Hao Shi, Chenxi Qian, Xinran Dong, et al.

    Single-cell transcriptomics data present challenges due to their inherent stochasticity and sparsity, complicating both cell clustering and cell type-specific network inference. To address these challenges, we introduce scMINER (single-cell Mutual Information-based Network Engineering Ranger), an integrative framework for unsupervised cell clustering, transcription factor and signaling protein network inference, and identification of hidden drivers from single-cell transcriptomic data. scMINER demonstrates superior accuracy in cell clustering, outperforming five state-of-the-art algorithms and excelling in distinguishing closely related cell populations. For network inference, scMINER outperforms three established methods, as validated by ATAC-seq and CROP-seq. In particular, it surpasses SCENIC in revealing key transcription factor drivers involved in T cell exhaustion and Treg tissue specification. Moreover, scMINER enables the inference of signaling protein networks and drivers with high accuracy, which presents an advantage in multimodal single cell data analysis. In addition, we establish scMINER Portal, an interactive visualization tool to facilitate exploration of scMINER results.


  • Open Access

    Integrated Whole Genome and Transcriptome Sequencing as a Framework for Pediatric and Adolescent AML Diagnosis and Risk Assessment

    by Lu Wang, Rebecca Voss, Victor Pastor, Maria Cardenas, Priyadarshini Kumar, Jamie Maciaszek, Maria Namwanje, Jing Ma, Jennifer Neary, Meiling Jin, et al.

    Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic significance. Emerging rare, recurrent genetic abnormalities and their associations with outcomes emphasize the need for high-throughput molecular diagnostic tools. Whole genome sequencing (WGS) reliably detects key AML biomarkers such as structural variants, mutations, and copy number alterations. Whole transcriptome sequencing (WTS) complements WGS by uncovering oncogene expression patterns, allele-specific expression, and gene expression signatures. In this study, we describe an integrated WGS and WTS clinical workflow for routine pediatric AML diagnosis and present a systematic evaluation of its application compared to conventional cytogenetics and standard molecular diagnostic methods. Our findings demonstrate that the integrated WGS and WTS (iWGS-WTS) approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Moreover, with advancements in workflow and bioinformatics pipelines, the testing turnaround time can be optimized to meet the demands of clinical decision-making, positioning iWGS-WTS as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.


  • Open Access

    Supplementary Note from Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia

    by Esmé Waanders, Zhaohui Gu, Stephanie M. Dobson, Željko Antić, Jeremy Chase Crawford, Xiaotu Ma, Michael N. Edmonson, Debbie Payne-Turner, Maartje van de Vorst, Marjolijn C.J. Jongmans, et al.

    Supplementary results, figures, and table notes